Crispr Therapeutics AG vs SiTime Corporation — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while SiTime Corporation trades at $689.5 (market cap $20.05B). The key difference: SiTime Corporation is far larger — about 3.8× Crispr Therapeutics AG's market cap, and SiTime Corporation is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SITM | |
|---|---|---|
Market Cap | $5.23B | $20.05B |
Sector | Health | Technology |
52-Week High | $76.78 | $901.60 |
52-Week Low | $44.34 | $212.77 |
Enterprise Value | $3.65B | $19.45B |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →